Tandem Transplant for High-Risk Neuroblastoma

Bagatell, Rochelle; Irwin, Meredith S.

doi:10.1001/jama.2019.11641

Cited by 4 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The trial was therefore not able to address whether tandem transplant is a benefit for all-comers with highrisk neuroblastoma. 47 High-dose therapy with MEC following GPOH induction arguably provides some of the strongest evidence for transplant given length of follow-up, significant improvements in both EFS and OS, and results also favoring transplant among patients who went on to receive immunotherapy. Even so the study had limitations, including a subset of patients in the transplant arm receiving prior 131 I-MIBG therapy and the comparator arm comprising only three months of single-agent cyclophosphamide.…”

Section: Discussionmentioning

confidence: 99%

“…In COG‐ANBL0532, 207 of 652 eligible patients did not undergo randomization because of physician or family preference. The trial was therefore not able to address whether tandem transplant is a benefit for all‐comers with high‐risk neuroblastoma 47 . High‐dose therapy with MEC following GPOH induction arguably provides some of the strongest evidence for transplant given length of follow‐up, significant improvements in both EFS and OS, and results also favoring transplant among patients who went on to receive immunotherapy.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

To transplant, or not to transplant? That is the question. A patient advocate evaluation of autologous stem cell transplant in neuroblastoma

Bird

Scobie²,

Palmer³

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

High-dose chemotherapy with autologous stem cell transplant (ASCT) has been a mainstay of high-risk neuroblastoma treatment for several decades, demonstrating improvements in event-free survival but with risks of serious or even life-threatening acute toxicities, severe long-term adverse health effects for survivors, and ongoing contention regarding overall survival benefit. The merits of ASCT in the modern era of immunotherapy are a source of debate among parents, advocates, and some physicians. Here we examine evidence for and against ASCT, explore parent attitudes and their turmoil over decision-making, and strongly encourage international research consortia to develop a coordinated strategy to accelerate progress toward a future that avoids the routine use of ASCT in high-risk neuroblastoma.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

To transplant, or not to transplant? That is the question. A patient advocate evaluation of autologous stem cell transplant in neuroblastoma

Bird

Scobie²,

Palmer³

et al. 2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

show abstract

“…Non‐Hispanic API and non‐Hispanic AIAN cases were grouped into the category non‐Hispanic all other races to allow for comprehensive analysis given the limited number of cases in these groups. Diagnosis during 2001–2009 was compared to diagnosis during 2010–2018 to align with treatment changes instituted by the Children's Oncology Group 13 . Statistical testing for survival curves was performed using the log‐rank test.…”

Section: Methodsmentioning

confidence: 99%

A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019

Campbell,

Siegel,

Umaretiya

et al. 2023

Pediatric Blood & Cancer

View full text Add to dashboard Cite

BackgroundWe characterize the incidence and 5‐year survival of children and adolescents with neuroblastoma stratified by demographic and clinical factors based on the comprehensive data from United States Cancer Statistics (USCS) and the National Program of Cancer Registries (NPCR).MethodsWe analyzed the incidence of neuroblastoma from USCS (2003–2019) and survival data from NPCR (2001–2018) for patients less than 20 years old. Incidence trends were calculated by average annual percent change (AAPC) using joinpoint regression. Differences in relative survival were estimated comparing non‐overlapping confidence intervals (CI).ResultsWe identified 11,543 primary neuroblastoma cases in USCS. Age‐adjusted incidence was 8.3 per million persons [95% CI: 8.2, 8.5], with an AAPC of 0.4% [95% CI: −0.1, 0.9]. Five‐year relative survival from the NPCR dataset (n = 10,676) was 79.7% [95% CI: 78.9, 80.5]. Patients aged less than 1 year had the highest 5‐year relative survival (92.5%). Five‐year relative survival was higher for non‐Hispanic White patients (80.7%) or Hispanic patients (80.8%) compared to non‐Hispanic Black patients (72.6%).ConclusionNeuroblastoma incidence was stable during 2003–2019. Differences in relative survival exist by sex, age, race/ethnicity, and stage; patients who were male, older, non‐Hispanic Black, or with distant disease had worse survival. Future studies could seek to assess the upstream factors driving disparities in survival, and evaluate interventions to address inequities and improve survival across all groups.

show abstract

Tandem high-dose multiagent chemotherapy followed by autologous stem cell transplantation in children with high-risk neuroblastoma

Smirnova

2024

Voprosy gematologii/onkologii i immunopatologii v pediatrii

View full text Add to dashboard Cite

The improvement of treatment outcomes for children with high-risk neuroblastoma is one of the most significant challenges in current pediatric oncology/hematology practice. Treatment outcomes in these patients need to be improved, both in terms of achieving remission and in terms of toxicity profile. At the present time, a number of approaches have been adopted to achieve better outcomes, including the intensification of treatment by using tandem high-dose multiagent chemotherapy followed by autologous hematopoietic stem cell transplantation as a part of treatment. Tandem high-dose chemotherapy with autologous hematopoietic stem cell transplantation has been shown to be effective and safe in several studies. The purpose of this literature review is to present research data showing the feasibility and safety of this treatment strategy in practice.

show abstract

Tandem Transplant for High-Risk Neuroblastoma

Cited by 4 publications

References 21 publications

To transplant, or not to transplant? That is the question. A patient advocate evaluation of autologous stem cell transplant in neuroblastoma

To transplant, or not to transplant? That is the question. A patient advocate evaluation of autologous stem cell transplant in neuroblastoma

A comprehensive analysis of neuroblastoma incidence, survival, and racial and ethnic disparities from 2001 to 2019

Tandem high-dose multiagent chemotherapy followed by autologous stem cell transplantation in children with high-risk neuroblastoma

Contact Info

Product

Resources

About